← Russell 3000 cross-section

AVR Anteris Technologies Global Corp.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$888m
Revenue TTM
$2m
Net income TTM
$-104m
Free cash flow
$-88m
Composite score
36.7
Sector rank
#2082

Valuation

P / E
EV / EBITDA
EV / sales
284.5
FCF yield
-9.94%
Earnings yield vs 10-yr
-16.40pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-4,619.3%
EBITDA margin
-4,660.8%
ROE
-41.2%
ROIC
-7,163.4%
Revenue growth
-9.6%

Insider activity, last 90 days

Net open-market
$-25.07m
Buyers
1
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net Sales Net sales for the three months ended June 30, 2026 were $1.0 million, compared to $0.6 million for the same period in the prior year, representing an increase of $0.4 million (63%). The increase primarily reflects increased sales of tissue products to 4C. Net sales for the six months ended June 30, 2026 were $1.5 million, compared to $1.2 million for the same period in the prior year, representing an increase of $0.3 million (28%). The increase primarily reflects increased sales of tissue products to 4C and was partially offset by the cessation of sales of CardioCelâ„¢ and VascuCelâ„¢ products under the Transition Services Agreement with LeMaitre, which expired in January 2025. …Anteris Technologies Global Corp., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →